PMP22 and Charcot-Marie-Tooth disease type 1A: After in vitro validation of siRNA PMP22-SQ NPs, their therapeutic efficacy was tested in two transgenic mouse models of CMT1A, named JP18 and JP18/JY13, carrying respectively one and two extra copies of the PMP22 gene and developed on a B6 background32.